Logo image of MYNZ

MAINZ BIOMED NV (MYNZ) Stock Fundamental Analysis

NASDAQ:MYNZ - Nasdaq - NL0015000LC2 - Common Stock - Currency: USD

6.09  +0.75 (+14.04%)

After market: 6.5154 +0.43 (+6.99%)

Fundamental Rating

2

Overall MYNZ gets a fundamental rating of 2 out of 10. We evaluated MYNZ against 572 industry peers in the Biotechnology industry. MYNZ has a bad profitability rating. Also its financial health evaluation is rather negative. MYNZ is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MYNZ has reported negative net income.
MYNZ had a negative operating cash flow in the past year.
In the past 5 years MYNZ always reported negative net income.
In the past 5 years MYNZ always reported negative operating cash flow.
MYNZ Yearly Net Income VS EBIT VS OCF VS FCFMYNZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -5M -10M -15M -20M -25M

1.2 Ratios

MYNZ has a Return On Assets of -311.04%. This is amonst the worse of the industry: MYNZ underperforms 94.69% of its industry peers.
Industry RankSector Rank
ROA -311.04%
ROE N/A
ROIC N/A
ROA(3y)-139.16%
ROA(5y)-127.77%
ROE(3y)-393.42%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MYNZ Yearly ROA, ROE, ROICMYNZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 -200 -400 -600 -800

1.3 Margins

Looking at the Gross Margin, with a value of 56.91%, MYNZ is in the better half of the industry, outperforming 78.41% of the companies in the same industry.
MYNZ's Gross Margin has improved in the last couple of years.
MYNZ does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 56.91%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y32.46%
GM growth 5YN/A
MYNZ Yearly Profit, Operating, Gross MarginsMYNZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K -5K

More info and screens

0

2. Health

2.1 Basic Checks

MYNZ does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MYNZ has less shares outstanding
Compared to 1 year ago, MYNZ has a worse debt to assets ratio.
MYNZ Yearly Shares OutstandingMYNZ Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 5M 10M
MYNZ Yearly Total Debt VS Total AssetsMYNZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -20.42, we must say that MYNZ is in the distress zone and has some risk of bankruptcy.
MYNZ has a worse Altman-Z score (-20.42) than 87.26% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -20.42
ROIC/WACCN/A
WACC6.3%
MYNZ Yearly LT Debt VS Equity VS FCFMYNZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 10M -10M -20M

2.3 Liquidity

A Current Ratio of 0.24 indicates that MYNZ may have some problems paying its short term obligations.
MYNZ has a Current ratio of 0.24. This is amonst the worse of the industry: MYNZ underperforms 96.64% of its industry peers.
MYNZ has a Quick Ratio of 0.24. This is a bad value and indicates that MYNZ is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.19, MYNZ is not doing good in the industry: 96.99% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.24
Quick Ratio 0.19
MYNZ Yearly Current Assets VS Current LiabilitesMYNZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 5M 10M 15M

More info and screens

7

3. Growth

3.1 Past

The earnings per share for MYNZ have decreased strongly by -3381.64% in the last year.
MYNZ shows a strong growth in Revenue. In the last year, the Revenue has grown by 68.96%.
MYNZ shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 22.26% yearly.
EPS 1Y (TTM)-3381.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3487.15%
Revenue 1Y (TTM)68.96%
Revenue growth 3Y22.26%
Revenue growth 5YN/A
Sales Q2Q%109.99%

3.2 Future

Based on estimates for the next years, MYNZ will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.58% on average per year.
MYNZ is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 156.06% yearly.
EPS Next Y-1367.8%
EPS Next 2Y-139.21%
EPS Next 3Y16.86%
EPS Next 5Y14.58%
Revenue Next Year13.81%
Revenue Next 2Y22%
Revenue Next 3Y113.85%
Revenue Next 5Y156.07%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MYNZ Yearly Revenue VS EstimatesMYNZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M
MYNZ Yearly EPS VS EstimatesMYNZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -20 -40 -60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MYNZ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MYNZ. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MYNZ Price Earnings VS Forward Price EarningsMYNZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MYNZ Per share dataMYNZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

A more expensive valuation may be justified as MYNZ's earnings are expected to grow with 16.86% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-139.21%
EPS Next 3Y16.86%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MYNZ!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MAINZ BIOMED NV

NASDAQ:MYNZ (1/31/2025, 8:00:01 PM)

After market: 6.5154 +0.43 (+6.99%)

6.09

+0.75 (+14.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-11 2024-11-11/bmo
Earnings (Next)N/A N/A
Inst Owners0.47%
Inst Owner ChangeN/A
Ins Owners16.54%
Ins Owner ChangeN/A
Market Cap13.52M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short Ratio0.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)13.33%
EPS NY rev (1m)0%
EPS NY rev (3m)-2597.14%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-47.37%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-10.78%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 15.1
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.64
EYN/A
EPS(NY)-9.38
Fwd EYN/A
FCF(TTM)-9.06
FCFYN/A
OCF(TTM)-8.7
OCFYN/A
SpS0.4
BVpS-1.86
TBVpS-3.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -311.04%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 56.91%
FCFM N/A
ROA(3y)-139.16%
ROA(5y)-127.77%
ROE(3y)-393.42%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y32.46%
GM growth 5YN/A
F-Score3
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 88.5%
Cap/Sales 89.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.24
Quick Ratio 0.19
Altman-Z -20.42
F-Score3
WACC6.3%
ROIC/WACCN/A
Cap/Depr(3y)140.47%
Cap/Depr(5y)87.62%
Cap/Sales(3y)113.34%
Cap/Sales(5y)68.41%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3381.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3487.15%
EPS Next Y-1367.8%
EPS Next 2Y-139.21%
EPS Next 3Y16.86%
EPS Next 5Y14.58%
Revenue 1Y (TTM)68.96%
Revenue growth 3Y22.26%
Revenue growth 5YN/A
Sales Q2Q%109.99%
Revenue Next Year13.81%
Revenue Next 2Y22%
Revenue Next 3Y113.85%
Revenue Next 5Y156.07%
EBIT growth 1Y-0.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-104.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-102.2%
OCF growth 3YN/A
OCF growth 5YN/A